Biopreservation Market Size, Key Companies, Company Market Share, Biopreservation Product Demand, Cell Provider Volume, Biobanking Adoption, R&D Investments, and Demand Forecast

Revenue, 2026

USD 5.28 Bn

Forecast Year, 2035

USD 39.35 Bn

CAGR, 2026 - 2035

25.35%

Report Coverage

Global

What is the Biopreservation Market Size?

The global biopreservation market size is accounted at USD 4.11 billion in 2025 and predicted to increase from USD 5.28 billion in 2026 to approximately USD 39.35 billion by 2035, representing a CAGR of 25.35% from 2026 to 2035.

Biopreservation Market Key Takeaways

• North America dominated the global biopreservation market with the largest market share of 47% in 2025.
• By product, the media industry will likely develop at a 30.6% CAGR from 2026 to 2035.
• By volume, the iPSC segment is predicted to grow significantly during the forecast period due to its ability to multiply indefinitely and its usage in restorative therapy.
• By application, the biobanking segment dominated the global market. The regenerative medicine segment is expected to develop at the quickest CAGR of 30.3% over the forecast period, owing to increased demand for technologically upgraded bio-storage techniques.

Market Overview

Biopreservation employs microorganisms and their metabolic by-products to boost food safety and shelf life. It keeps biospecimens alive for longer periods and protects them from harm outside of their natural environment. Biospecimens are material samples like urine, tissue, blood, DNA, cells, and others stored in a bio repository for future research or used in laboratory tests.

Bio-preservation media and bio-preservation equipment are the two basic types of bio-preservation. Bio-preservation equipment includes tools that preserve biospecimens such as bio-based therapeutics, cells, clinical biomarkers, diagnostic biochips, viruses, etc. Many biospecimens, such as human tissue samples, stem cells, organs, and others, are processed using it.

Improving healthcare expenditure, implementing in-house storage of samples in labs and hospitals, and increasing R&D investment are all factors driving the market growth.

Biopreservation is critical in the advancement of regenerative medicine. The increase in investment for bio-preservation-based pharmaceutical businesses to meet the growing need for tissue and cell preservation is expected to drive market growth. For example, X-Therma Inc., a biotechnology business developing organ preservation and regenerative medicine technology, completed an oversubscribed USD 13 million Series A fundraising round in December 2021. LOREA AG, an entrepreneur-run investment firm, handled the fundraising, including involvement from renowned return angel investors and Graphene Ventures, Zen11 Holdings, Methuselah Foundation, V.U. Venture Partners, and others.

Biopreservation Market Growth Factors

Increasing investments in research and developments, biobanking advancements, and the growing practice of preserving newborn cord blood stem cells are significant factors predicted to propel the market throughout the forecast period. Rising investments in research of regenerative medicine, as well as rising demand for personalized treatment, are driving the biopreservation market growth.

Some of the primary drivers expected to drive market expansion throughout the forecast period include advancements in the hypothermic storage solutions formulation, next-generation systems of cryopreservation, and design and integration with nanoscale technologies.

Furthermore, technological developments, increased product approvals, alliances, and acquisitions by key companies are assisting in market expansion. For example, Guy's and St Thomas' Hospital in the United Kingdom will begin a fertility preservation service for ovarian tissue cryopreservation for women receiving cancer treatment in February 2022. Growing technological developments and launches in biopreservation, as well as the cost-effectiveness of these devices, are likely to generate attractive chances for target market expansion throughout the timeframe specified.

Market Scope

Market Dynamics

Drivers

The rising prevalence of chronic illnesses, the advancement of regenerative medicine, and the growth of biospecimen testing are the primary factors driving the market growth.

The increased frequency of obesity and chronic diseases worldwide is one of the primary reasons driving the market growth. Patients with chronic diseases such as diabetes, heart disease, and degenerative illnesses affecting joints, nerves, and bones, among others, are increasing the demand for biopreservation.

The growing number of patients has significantly burdened the healthcare industry with utilizing improved biospecimen preservation techniques. This has resulted in the widespread adoption and use of bio-preservation technology, facilitating market expansion. Regenerative medications manage and treat various chronic illnesses and degenerative ailments.

To maintain the integrity and efficacy of regenerative treatments, biopreservation techniques are widely used. The increasing use of regenerative medicine has directly contributed to the exponential growth in demand for biopreservation. Furthermore, increased testing by the general public due to various health issues has raised the demand for the healthcare industry to retain biospecimens. The increasing preservation workload has directly raised the need for biopreservation approaches.

Restraints

The high costs of biopreservation activities

Biopreservation is an advanced preservation technology with significant expenses due to the expensive processes and equipment utilized throughout the preservation process. Biopreservation also has significant stability concerns due to tissue damage during freezing and thawing. Furthermore, the introduction of low-cost preservation procedures like processes of room temperature preservation will hinder market growth.

Opportunities

Increasing investments in research and development of new drugs, increasing biobanks, and government attempts to create profitable market opportunities.

Major investments have been made by private and public organizations in research and development efforts connected to the creation of new medications, which could potentially assist in fighting the growing number of chronic diseases. The significant increase in expenditure is intended to provide access to superior medical care and advanced products, including biopreservation facilities.

The growing number of biobanks that especially maintain biospecimens has provided significant potential opportunities for the biopreservation market. Governments throughout the world are adopting a variety of steps to encourage cell therapies for the cure of different diseases. Government healthcare efforts provide grants, contracts, and cash for research work, resulting in increased R&D expenditure by organizations.

Segments Insights

Product Insights

Due to increased demand for bio-banking for storing DNA, stem cells, plasma, and tissue culture, the equipment category represented the greatest revenue share in 2025. The broad adoption and use of preservation have resulted in low maintenance and sufficient storage capacity, which is anticipated to drive market growth.

From 2025 to 2034, the media sector is predicted to grow at a lucrative CAGR of 30.6%. The market has the potential to expand because it is an important aspect of the biopreservation method. Media applications provide more features and information that enable researchers to access and share research data and analysis, enhancing their ability to research, monitor, diagnose, and treat health conditions, which are expected to boost the market during the forecast period.

Cell Providers Volume Insights

Tumor cells had the highest revenue share in 2025. This is due to an increase in cancer research, diagnosis, and treatment activities involving the creation of cancer therapies. Tumor cells, including colon, prostate, and breast carcinomas, are used as biomarkers in cancer research. The clinical value of tumor cells has aided the segment's expansion.

Because of its potential to replicate indefinitely, the iPSC segment is expected to rise significantly throughout the forecast period due to its use in therapeutic therapy. It encompasses a broad spectrum of biological studies focused on cells, including disease models, drug discovery, organ manufacturing, RBCs, and tissue repair. Rising finance support provides an additional lucrative prospect for business growth.

Application Insights

The biobanking category led the worldwide market. Rising knowledge of stem cell preservation, increased acceptance of egg and sperm banking, and use of animal-assisted reproductive technologies are driving the segment's growth. Pharmaceutical corporations work with reserve biobanks and hospitals to preserve tissue.

Due to the rising demand for technologically enhanced bio-storage techniques, the regenerative medicine category is predicted to grow at the fastest CAGR of 30.3% during the forecast period. Furthermore, introducing specific preservation procedures will drive industry expansion in the coming years.

Regional Insights

U.S. Biopreservation Market Size and Growth 2026 To 2035

The U.S. biopreservation market size reached USD 1,340 million in 2025 and is anticipated to reach around USD 13,205 million by 2035, poised to grow at a CAGR of 25.71% from 2026 to 2035.

How did North America hold the Highest Revenue Share in the Biopreservation Market?

North America is leading the market with the highest revenue share. This is due to advances in biomedical research and the development of improved medicines. Furthermore, the increasing prevalence of chronic diseases necessitating treatment increases demand for biopreservation in the region, bolstering its market position. These actions will likely contribute to expanding biopreservation products on the market, hence propelling growth. The United States is expected to increase significantly during the forecasted period due to government organizations and numerous biobanking institutes contributing to the spread of biopreservation techniques.

U.S. Biopreservation Market Analysis

The U.S. advances with the rising trends such as regenerative medicine, cell therapies, personalized medicine, and the expansion of biobanking. In December 2025, a Senate bill was introduced to accelerate biopharmaceutical manufacturing in America. In April 2025, the U.S. Department of Energy (DOE) Bioenergy Technologies Office (BETO) announced the funding of $12 million to support and advance biorefinery technologies for biochemicals and biofuels.

For example, the National Institutes of Health (NIH) funds biospecimen collection in biobanks and biorepositories, while the National Cancer Institute (NCI) assists with managing such bio-banking programs. These biobanks help fund clinical trials and research programs in the United States, which increases the need for biopreservation techniques.

What makes Asia Pacific the Fastest-Growing Region in the Biopreservation Market?

Asia Pacific is expected to grow at the fastest rate in the market during the forecast period, owing to government and private federal funding in R&D by agencies like the National Institutes of Health (NIH) to drive innovation. The Asia-Pacific Biopesticide Community of Practice (ABCoP) offers a platform to unite major players in the biopesticide sector, including researchers, policymakers, government agencies, industry leaders, NGOs, and other stakeholders from the Asia-Pacific region.

China Market Trends

China holds substantial growth in the biopreservation market, driven by the presence of a sophisticated healthcare infrastructure, rapid expansion of the biotechnology and biopharmaceutical sectors, growing network of biobanks, growing demand for viral vectors, rising investments in regenerative medicine, increasing volume of clinical trials, and a supportive government framework. Moreover, the rising transition from clinical trials to commercial distribution in cell and gene therapies creates a massive need for standardized freezing media and cryogenic transport solutions.

How did Europe reach notable growth in the Biopreservation Market?

Europe is expected to be the most attractive segment of the market during the forecast period. Germany is predicted to progress the quickest in Europe over the forecast period, owing to increased funding support for biobanking techniques and services and increased partnerships and collaborations, including bio-preservation techniques.

UAE Market Trends

Germany is witnessing notable market growth. The country's growth is largely driven by the robust presence of the biotechnology sector, expanding biobank infrastructure, increasing expansion of gene therapy and cell therapy pipelines, and favourable government policies. Moreover, the rising prevalence of chronic disorders, along with the rising aging population, has significantly increased the demand for advanced treatments, precision medicine, and biological specimen storage. Such a combination of factors is anticipated to propel the growth of the biopreservation market during the forecast period.

Germany Biopreservation Market Trends

The German market is witnessing an increased consumer demand for clean-label products, government support and regulations, favorable reimbursement policies, and stringent safety standards. The expansion of biobanking initiatives, personalized medicine, and regenerative therapies is driving the need for robust biopreservation protocols and specialized consumables. Regulatory emphasis on quality, traceability, and biosafety, as well as investments in R&D and collaborations between research institutions and industry, are strengthening market development.

What is the Potential of the Biopreservation Market in Latin America?

Latin America is expected to grow at the fastest rate in the market due to the remarkable efforts made by this region to conserve some of the most valuable ecosystems in the world. This region remains the home to 40% of the world's known species, and is one of the most biodiverse regions of the world.

What Opportunities Exist in the Biopreservation Market in the Middle East & Africa?

The Middle East and Africa are expected to grow at a lucrative rate in the market, owing to cold chain logistics, the rising demand for advanced therapies, and the expanding clinical infrastructure and biobanking. Governments in the Middle East and North Africa (MENA) highly support circularity and biomanufacturing through regulation, policy, and roadmaps.

Competitive Landscape

The biopreservation market is driven by a shift towards clean-label and plant-based products, urbanization, packaged diet logistics, active intelligent packaging, tech-driven diagnostic tools, etc. The top companies in the market are Thermo Fisher Scientific Inc., BioLife Solutions, Inc., Azenta, Inc., Danaher Corporation, and Cryoport, Inc. The core product offerings are HypoThermosol FRS, CryoStor cryopreservation media, PanTHERA IRI technology, CryoMed controlled rate freezers, and many more. The R&D capital is directed toward vitrification processes, which prevent ice-crystal formation entirely.

Hardware manufacturers are focusing R&D on automated cloud-monitored smart freezers and cryogen-free technologies to reduce manual error. The primary R&D biopreservation focus has been shifted toward automated repository systems, high-density automated sample storage, next-gen cryo-electron microscopy, AI-driven automated structural imaging, specialized chemical media, AI-driven inventory analytics, and more.

Company Profiles

Biomatrica, Inc.

• HQ: San Diego, California, United States
• Founded: 2004
• Ownership: Owned by Exact Sciences Corporation, a major molecular diagnostics and cancer screening company
• Business Overview: Biomatrica, Inc. is expanding the multi-billion-dollar biopreservation and biobanking consumables sector and serves clinical diagnostics, academic groups, pharmaceutical R&D, and forensics. The company is a specialized biotechnology developer of chemical stabilization technologies.
• Products: DNA preservation products, RNA preservation products, cellular and clone preservation products, and sample management software.
• Geographic Presence: The facility in the U.S. handles core research, development, and administrative operations for biostability and sample preservation technologies.
• Revenue: Biomatrica, Inc. raised $33.1 million to $41.3 million in venture funding.
• Recent Development: In February 2026, research studies stated that the biopreservation market was estimated to reach US$ 44.45 billion by 2035. This growth was supported by the expansion of the cold chain and commercialization of cell and gene therapy.
• Key Strategies: Biomimetic technology exploitation, eliminating cold chain logistics, strategic B2B partnerships and integration, continuous expansion of the pre-analytic pipeline, assay preservation services, eco-friendly green alternative.

Azenta US, Inc.

• HQ: 200 Summit Drive, Burlington, Massachusetts 01803, USA
• Founded: 1978
• Ownership: Publicly traded parent company
• Business Overview: Azenta US, Inc. offers cold-chain sample management and biopreservation solutions and specializes in biological sample repositories, automated cryogenic storage systems, multiomics services, and sample tracking consumables. These product offerings are tailored for top biotechnology, pharmaceutical, and academic institutions.
• Products: Automated sample storage systems, cryogenic laboratory freezers and logistics, precise thawing solutions, consumables, labware, sample management software, and scanning.
• Geographic Presence: Azenta US, Inc. operates major business activities and facilities across Europe, North America, and Asia.
• Revenue: Azenta US Inc. generated revenue of $161.18 million for the third quarter of fiscal 2026.
• Recent Development: In March 2026, Azenta announced the completion of the strategic acquisition of UK Biocentre Limited to expand biorepository capabilities. This acquisition has strengthened Azenta's ability to offer end-to-end lifecycle solutions in the UK.
• Key Strategies: End-to-end sample lifecycle integration, scaling multiomics and synthesis capabilities, standardised commercial and operational discipline, and sustainable and eco-friendly infrastructure.

MVE Biological Solutions

• HQ: Ball Ground, Georgia, United States
• Founded: 1966
• Ownership: Owned by Cryoport, Inc., which acquired the company from Chart Industries
• Business Overview: MVE Biological Solutions is a leading manufacturer of vacuum-insulated containers, cryogenic freezing equipment, and temperature-controlled storage systems for the biopharmaceutical, life sciences, and animal health industries. The company launched real-time condition monitoring systems for cryogenic dewars and expanded its intelligent asset management portfolio.
• Products: Smart ecosystem and connected freezers, high-efficiency and eco-friendly cryogenic freezers, integrated logistics, advanced condition monitoring, and specialized aluminum dewars and shippers.
• Geographic Presence: MVE Biological Solutions operates across 48 locations and 17 countries globally, and distributes products to 88 countries across the world.
• Revenue: MVE Biological Solutions reported annual revenue of $7.6 million in 2026.
• Recent Development: In February 2026, MVE Biological Solutions launched the MVE Fusion 800 Series, the next evolution of MVE Biological Solutions' fusion technology. This self-sustaining cryogenic freezer delivers exceptional reliability, sustainability, and safety, and removes the need for a continuous liquid nitrogen (LNâ‚‚) supply.
• Key Strategies: Smart IoT, real-time monitoring integration, infrastructure-independent product innovation, market diversification across high-value sectors, regulatory rigor, strategic hub placement, etc.

BioLife Solutions

• HQ: Bothell, Washington, United States
• Founded: 1987
• Ownership: Publicly traded company owned by public shareholders and major institutional investors.
• Business Overview: BioLife Solutions has transitioned into a pure-play cell processing company and is recognized as a leading supplier of high-value biopreservation media for the cell and gene therapy industry.
• Products: Biopreservation and freeze media, cell performance and media supplements, cell processing and closed systems, cell thawing media, fluid management accessories, etc.
• Geographic Presence: BioLifeSolutions operates globally with its primary operational hub and corporate headquarters situated in Bothell, Washington, United States.
• Revenue: BioLifeSolutions generated revenue of $28.5 million for the second quarter of 2026.
• Recent Development: In November 2025, BioLifeSolutions inaugurated the biopreservation center in Washington to support cell and gene therapy manufacturing. This facility was designed to enable optimization, evaluation, and training services on cell-processing and biopreservation workflows for cell-based therapeutic developers.
• Key Strategies: Pure-play consumables portfolio, maximizing workflow embedding and high switching costs, targeted M&A for workflow enhancements, and scaling up-market to CDMOs and biopharma.

LabVantage Solutions, Inc.

• HQ: Somerset, New Jersey, United States
• Founded: 1981
• Ownership: Owned by The Chatterjee Group (TCG), a global private equity and investment firm
• Business Overview: LabVantage Solutions, Inc. offers enterprise laboratory software and informatics that support sample tracking, biobanking, and cold-chain data integrity within the biopreservation sector. The company integrates with IoT sensors to monitor freezer and storage temperatures in real time.
• Products: LabVantage biobanking LIMS for sample inventory and storage mapping, sample management assistance, smart IoT and mobile informatics, BioTech360 suite, LabVantage LIMS Version 8.9 for open talk interactive experience, etc.
• Geographic Presence: The professional services of LabVantage Solutions, Inc. are active on six continents and have a strong presence in Somerset, New Jersey, with nearly 40 locations globally.
• Revenue: The company reported an estimated annual revenue between $50 million and $1.0 billion.
• Recent Development: In March 2026, LabVantage Solutions, Inc. launched the Cortex platform that integrates analytics, AI, and automation to assist laboratories in reducing errors, improving efficiency, and obtaining detailed information from data.
• Key Strategies: Pioneer the autonomous lab ecosystem, intelligent automation, end-to-end connectivity, SaaS and hybrid deployment, customer success services portfolio, regional expansion, and strategic partnerships.

Biopreservation Market Companies

• Biomatrica, Inc.
• Azenta US, Inc.
• MVE Biological Solutions
• BioLife Solutions
• LabVantage Solutions, Inc.
• Thermo Fisher Scientific, Inc.
• Taylor-Wharton
• Panasonic Corporation
• PrincetonCryo
• X-Therma Inc.
• Stirling Ultracold

Recent Developments

• In February 2026, CaseBioscience announced the launch of CaseCryo CTG DMSO, a next-generation cryopreservation solution developed to support clinical cell therapy development, at Advanced Therapies Week (ATW) 2026. The company also plans to introduce CaseStor HSS Hypothermic Storage Solution, designed for the controlled hypothermic storage of cells and tissues. Together, these product introductions expand CaseBioscience 's biopreservation portfolio. (Source: https://www.biospace.com)
• In November 2025, BioLife Solutions announced the opening of its Aby J. Mathew Center for Biopreservation Excellence at its manufacturing campus in Bothell, Washington. The facility is designed to enable offering evaluation, optimization, and training services on biopreservation and cell-processing workflows to cell-based therapeutic developers. (Source: https://www.bioprocessintl.com)
• In November 2025, BioLife inaugurated a biopreservation center in Washington to support cell and gene therapies (CGTs) and related manufacturing. The center also offers evaluation, optimization, and training services on cell processing and biopreservation workflows to cell-based therapeutic developers. (Source: https://www.bioprocessintl.com)
• In December 2025, Biome Bioplastics and Renaissance BioScience launched a $1.5 million initiative to scale renewable bioplastics. The initiative aims to develop a system to produce renewable and bio-based blocks for bioplastics through advanced fermentation. (Source: https://www.indianchemicalnews.com)

Segments Covered in the Report

By Product

• Equipment
  • Refrigerators
  • Freezers
  • Consumables
    • Straws
    • Vials
    • Microtiter Plates
    • Bags
  • Liquid Nitrogen
• Media
  • Home-brew
  • Pre-formulated
• Laboratory Information Management System (LIMS)

By Application

• Regenerative Medicine
  • Gene Therapy
  • Cell Therapy
  • Others
• Bio-banking
  • Human Sperms
  • Human Eggs
  • Veterinary IVF
• Drug Discovery

By Cell Providers Volume

• CD19+
• CD34+
• iPSC
• MSC
• Tumor Cells
• hESC
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa